Transforming growth factor β (TGF-β) is a potent inhibitor of proliferation in most cells and exerts its effects through an interaction with membrane receptors type I (TGF-βRI) and type II (TGF-βRII). Recently, we have demonstrated a correlation between the loss of expression of TGF- βRI and TGF-βRII and increasing Gleason score in archival human prostate cancer tissues. To evaluate the potential prognostic value of this observation, the present study investigated the expression of TGF-β receptors in association with disease progression after the initial diagnosis in 52 archival human prostate cancer tissues. The expression of both TGF- βRI and TGF-βRII was correlated with the Gleason score, clinical tumor stage, 4-year survival rate, and serological recurrence rate after radical prostatectomy. Results revealed that there was a significant association between the Gleason score and the loss of expression of TGF-βRI (P < 0.025) and TGF-βRII (P < 0.01). However, only the loss of TGF-βRI expression showed a statistically significant association with the clinical tumor stage (P < 0.05), 4-year survival rate (P < 0.05), and serological recurrence rate after radical prostatectomy (P < 0.025). Therefore, these data indicate that the loss of TGF-βRI expression as measured by immunohistochemical staining may be a potential prognostic marker in prostate cancer patients.
|Original language||English (US)|
|Number of pages||6|
|Journal||Clinical Cancer Research|
|State||Published - Jul 1998|
ASJC Scopus subject areas
- Cancer Research